Products - Skin cancer | Topic | NICE

Showing 54 products

Date | Title

AMBLor for identifying low-risk non-ulcerated early-stage cutaneous melanomas (MIB294)
Product type:
Advice
Programme:
Medtech innovation briefing
Published:
5 May 2022
Ambulight PDT for the treatment of non-melanoma skin cancer (MTG6)
Product type:
Guidance
Programme:
Medical technologies guidance
Published:
25 July 2011
Artificial intelligence (AI) technologies for assessing and triaging skin lesions within the urgent suspected skin cancer pathway
Status:
In development
Programme:
Health technology evaluation
Expected publication date:
19 December 2024
Avelumab for treating metastatic Merkel cell carcinoma (TA517)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
21 April 2021
Published:
11 April 2018
Avelumab for untreated metastatic Merkel cell carcinoma (TA691)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
21 April 2021
Bifikafusp alfa–onfekafusp alfa for neoadjuvant treatment of 3B or 3C resectable melanoma [ID6384]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Cemiplimab for treating advanced cutaneous squamous cell carcinoma (TA802)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
29 June 2022
Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck (TA473)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
31 August 2017
Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma (TA414)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
26 October 2016
Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma (TA321)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 October 2014
Dabrafenib, trametinib or both for treating BRAF V600 mutation-positive unresectable or metastatic melanoma in people aged 12 and over TS ID 11838
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma (TA544)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
17 October 2018
Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma in people aged 12 to 17 TS ID 11839
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Digital technologies for the detection of melanoma (MIB311)
Product type:
Advice
Programme:
Medtech innovation briefing
Published:
1 November 2022
EchoLaser percutaneous laser ablation treatment for patients with neck lesions
Status:
Topic selection
Programme:
Interventional procedures guidance
Expected publication date:
TBC
Electrochemotherapy for metastases in the skin from tumours of non-skin origin and melanoma (IPG446)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
27 March 2013
Electrochemotherapy for primary basal cell carcinoma and primary squamous cell carcinoma (IPG478)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
26 February 2014
Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma (TA562)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 February 2019
Endoscopic radical inguinal lymphadenectomy (IPG398)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
22 June 2011
Epidermal radiotherapy using rhenium-188 paste for non-melanoma skin cancer (IPG784)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
2 April 2024
Improving outcomes for people with skin tumours including melanoma (CSG8)
Product type:
Guidance
Programme:
Cancer service guideline
Last updated:
25 May 2010
Published:
22 February 2006
Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma (TA268)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
12 December 2012
Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma (TA319)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
23 July 2014
Lifileucel for previously treated unresectable or metastatic melanoma ID3863
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Melanoma: assessment and management (NG14)
Product type:
Guidance
Programme:
NICE guideline
Last updated:
27 July 2022
Published:
29 July 2015
Nivolumab for adjuvant treatment of completely resected melanoma at high risk of recurrence in people 12 years and over (terminated appraisal) (TA980)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
5 June 2024
Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease (TA684)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
17 March 2021
Nivolumab for treating advanced (unresectable or metastatic) melanoma (TA384)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
18 February 2016
Nivolumab in combination with ipilimumab for treating advanced melanoma (TA400)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 July 2016
Nivolumab–relatlimab for adjuvant treatment of resected stage 3 or 4 melanoma in people 12 years and over ID 6475
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and over (TA950)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
7 February 2024
Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma (TA865)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
8 February 2023
Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma (TA766)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
2 February 2022
Pembrolizumab for adjuvant treatment of locally advanced cutaneous squamous cell carcinoma after surgery and radiotherapy ID 6473
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma (TA837)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
26 October 2022
Pembrolizumab for advanced melanoma not previously treated with ipilimumab (TA366)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
12 September 2017
Published:
25 November 2015
Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab (TA357)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
12 September 2017
Published:
7 October 2015
Pembrolizumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (terminated appraisal) (TA570)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
20 March 2019
Photodynamic therapy for non-melanoma skin tumours (including premalignant and primary non-metastatic skin lesions) (IPG155)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
22 February 2006
Skin cancer (QS130)
Product type:
Quality standard
Last updated:
24 January 2024
Published:
21 September 2016
Skin cancer prevention (PH32)
Product type:
Guidance
Programme:
Public health guideline
Last updated:
9 February 2016
Published:
26 January 2011
Spartalizumab with dabrafenib and trametinib for untreated BRAF V600 mutation-positive unresectable or metastatic melanoma [ID1668]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
21 April 2021
Sunlight exposure: risks and benefits (NG34)
Product type:
Guidance
Programme:
NICE guideline
Published:
9 February 2016
Suspected cancer (QS124)
Product type:
Quality standard
Last updated:
5 December 2017
Published:
30 June 2016
Suspected cancer: recognition and referral (NG12)
Product type:
Guidance
Programme:
NICE guideline
Last updated:
2 October 2023
Published:
23 June 2015
Talimogene laherparepvec for treating unresectable metastatic melanoma (TA410)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 September 2016
Tiragolumab with atezolizumab for treating advanced oesophageal squamous cell cancer after chemoradiotherapy [ID6267]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Tislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy [ID4070]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Tislelizumab with chemotherapy for untreated advanced oesophageal squamous cell cancer [ID5113]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Toripalimab with chemotherapy for treating advanced oesophageal squamous cell cancer without previous systemic chemotherapy [ID6414]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma (TA396)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 June 2016
Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation‑positive malignant melanoma (TA269)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
1 January 2015
Published:
12 December 2012
Vismodegib for treating basal cell carcinoma (TA489)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 November 2017
VivaScope 1500 and 3000 imaging systems for detecting skin cancer lesions (DG19)
Product type:
Guidance
Programme:
Diagnostics guidance
Published:
11 November 2015